Kentucky Patent of the Month – June 2024

Omega Ophthalmics, LLC, a leader in ocular lens technology, has been granted a patent for their new prosthetic capsular device. This state-of-the-art implant is designed to revolutionize eye surgeries, particularly for patients requiring intraocular lenses (IOLs). The prosthetic capsular device is a monolithic, single-piece housing structure that fits seamlessly into the natural capsular bag of the eye. 

One of the standout features is its ability to house multiple refractive surfaces and IOLs, which can be easily inserted, removed, or replaced through the arcuate anterior opening. This design not only facilitates customization but also ensures long-term adaptability as patients’ visual needs change over time. The continuous anterior and posterior sidewalls form a secure groove that prevents any movement of the lenses, maintaining precise positioning and optimal performance.

Another significant innovation is the incorporation of drug release devices within the housing structure. These devices allow for the controlled release of medications directly into the eye, providing targeted treatment for various ocular conditions and reducing the need for frequent postoperative eye drops. This feature enhances patient comfort and compliance, contributing to better overall outcomes.

The prosthetic capsular device also boasts an enhanced biocompatibility profile, minimizing any protrusion into the natural capsular bag and thereby reducing inflammation and other potential complications. Its self-expandable nature ensures a snug fit within the eye, adapting perfectly to individual anatomical variations.

Orientation designation indicators and visual markers on the device ensure accurate placement during surgery, facilitating a smoother and more efficient procedure. This attention to detail underscores Omega Ophthalmics’ commitment to precision and patient safety.

With this pioneering technology, Omega Ophthalmics is setting a new standard in ophthalmic care, offering a versatile and highly effective solution for vision correction and eye health management. Their prosthetic capsular device represents a significant leap forward, promising improved outcomes and a higher quality of life for patients worldwide.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts